Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IDEA AG
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
Mereo will reduce its headcount by 40% to focus on its lead programs while NeuBase revealed a 60% workforce reduction to extend its cash runway. Also, Invivyd (formerly Adagio), Greenlight and BioMarin announced job cuts, while Otonomy and others planned strategic shifts.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
- In Vitro Diagnostics
- Topical Delivery
- Drug Delivery